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Abstract
Background: Chronic headache (headache≥ 15 days/month for at least 3 months) affects 2–5% of the general
population. Medication overuse contributes to the problem. Medication-overuse headache (MOH) can be identified
by using the Severity of Dependence Scale (SDS). A “brief intervention” scheme (BI) has previously been used for
detoxification from drug and alcohol overuse in other settings. Short, unstructured, individualised simple
information may also be enough to detoxify a large portion of those with MOH. We have adapted the structured
(BI) scheme to be used for MOH in primary care.
Methods/Design: A double-blinded cluster randomised parallel controlled trial (RCT) of BI vs. business as usual.
Intervention will be performed in primary care by GPs trained in BI. Patients with MOH will be identified through a
simple screening questionnaire sent to patients on the GPs lists. The BI method involves an approach for
identifying patients with high likelihood of MOH using simple questions about headache frequency and the SDS
score. Feedback is given to the individual patient on his/her score and consequences this might have regarding the
individual risk of medication overuse contributing to their headache. Finally, advice is given regarding measures to
be taken, how the patient should proceed and the possible gains for the patient. The participating patients
complete a headache diary and receive a clinical interview and neurological examination by a GP experienced in
headache diagnostics three months after the intervention. Primary outcomes are number of headache days and
number of medication days per month at 3 months. Secondary outcomes include proportions with 25 and 50%
improvement at 3 months and maintenance of improvement and quality of life after 12 months.
Discussion: There is a need for evidence-based and cost-effective strategies for treatment of MOH but so far no
consensus has been reached regarding an optimal medication withdrawal method. To our knowledge this is the
first RCT of structured non-pharmacological MOH treatment in primary care. Results may hold the potential of
offering an instrument for treating MOH patients in the general population by GPs.
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Background
Headache is a common health problem and the personal
burden, social impact and economic cost for both the
sufferers and society are substantial [1,2]. Most common
headaches are episodic tension-type headache (TTH)
and migraine [3]. However, 2–5% of the world’s popula-
tion have chronic headache [4-13] defined as 15 or more
headache days per month for at least 3 months and/or
180 or more headache days per year.
Headache is mostly self-managed [14,15] and headache
prescription medications account only partly for the
total medication use for headache since most patients
buy over-the-counter (OTC) drugs [5,6,16-19]. Headache
accounts for 4% of the general practitioners (GPs) con-
sultations [19], and is probably the most common reason
for referral to neurologists [19,20]. Approximately 20–30%
of all new referrals to out-patients neurological depart-
ments are due to headache [21,22].
Analgesic use, misuse and overuse represent major
health problems associated with numerous adverse health
consequences. A population-based study from Norway
which included about 50,000 subjects found that 10%
reported taking analgesics currently on a daily basis and
up to 5% reported taking analgesics on a daily basis for at
least six months [23]. Results from another Norwegian
study showed that 28% of men and 13% of women had
used analgesics over the preceding 28-day period, mostly
to treat headaches [24]. Frequent intake of analgesics
may, however, worsen headache and lead to chronifica-
tion and Medication Overuse Headache (MOH) [25-27].
MOH is a condition with chronic headache in com-
bination with overuse of acute headache medication(s)
[25-27]. The prevalence of MOH in the general popula-
tion is 1–2% [5,6,10,25-28]. The condition was first
described for egotamines in 1951 [29] and it is now sub-
stantiated that all drugs used for the acute treatment of
headache can cause MOH in patients with a pre-existant
headache disorder [25-27]. The proportion of MOH is
lower in the general population than one sees in clinical
settings, and the distribution of the overused medication
differs with simple analgesics being most frequently over-
used in the general population [7,9,17,28,30-35].
The aims of MOH management are [36,37]
i. withdrawal of the overused drug(s)
ii. to provide the patient with pharmacological and
non-pharmacological support
iii. to prevent relapse
Detoxification from the overused medication often leads
to headache improvement [25,26,31,38], but is often
complicated by temporary withdrawal symptoms such as
worsening of headache, nausea, vomiting, hypotension,
tachycardia, sleep disturbances, restlessness, anxiety and
nervousness which typically occur 2–10 days after de-
toxification [26,27,40,41]. There is no established optimal
withdrawal method for MOH though many different
strategies have been suggested [25,36,37,39]. These in-
clude use of antiemetics and/or neuroleptics to reduce
abstinence-like symptoms, intravenous administration of
ergotamines and substitution of the offending painkiller
with another. Steroid treatment has also been used to al-
leviate withdrawal reactions though this strategy is con-
troversal [36,37,41-43].
Regarding prophylactic headache medication, there is
also an ongoing discussion whether this should be
initiated immediately at withdrawal or after completed
withdrawal therapy [36,44].
Follow-up studies of various duration have reported
relapse rates between 20–60% and findings from these
studies suggest that patients have the highest risk of re-
lapse within the first year after withdrawal [37,45-49].
MOH is a heterogenous disorder which has been sug-
gested to include both subgroups with simple medication
overuse as well as more complex detoxification-resistant
cases [36,50-52]. Some of these cases may be more
“dependency-like” and it has indeed been suggested that
MOH shares some common neurobiological pathways
with drug dependence and that MOH therefore may
represents a kind of addictive behaviour [53]. Whether
this applies to all MOH cases or specific subgroups
defined by this particular “dependency-like” behaviour
(eg. “complex” MOH) remains to be demonstrated. Two
studies have demonstrated that most MOH patients ful-
fill criteria for dependency according to the Diagnostic
and Statistical Manual of Mental Disorders, fourth edi-
tion (DSM-IV) [54-56]. Another study found that the
dependency score based on the Leeds Dependency Ques-
tionnaire was similarly increased in MOH patients and
illegal drug addicts [57].
Over the past decades several dependency assessment
scales have been developed. The Severity of Dependence
Scale (SDS) is a simple, validated scale which scores psy-
chological dependence on a number of different sub-
stances [58-63]. Previous studies from our group have
revealed that the SDS has both high sensitivity, specifi-
city, positive and negative predictive values for detecting
persons with MOH among chronic headache patients.
[30,35,64]. In addition, the SDS score has been shown to
predict likelihood of successful detoxification in a general
population [65].
Screening and Brief Intervention (BI) is a well-known
approach to identify and treat unhealthy alcohol use
[66]. The SDS and similar scales such as the Alcohol
Use Disorders Identification test, have previously been
used to identify individuals at risk for addiction-related
problems [58-63,67-69]. BI involves the use of such an
identification tool followed by feedback to the identified
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individual as being “at risk”. The final step, in this very
short and simple intervention is to give information sug-
gesting to cut down the use of the particular substance
to predecided “acceptable” levels [66]. BI includes clear
directive advice, but focus is also on increasing patients
insight and awareness regarding overuse as described in
more detail elsewhere [66,70]. The BI method has shown
promising results with both short- and longlasting reduc-
tion of alcohol intake and levels of related biochemical
markers such as liver transferase levels [66,71-73]. Similar
methods have also been successfully applied for various
other addictive drugs [70,74,75].
We have previously reported data from an open, un-
controlled study of medication overuse headache in the
general population, which suggested that three out of
four MOH subjects had managed to reduce their medi-
cation intake after short information [76]. Similar sim-
ple advice also works in clinic settings [77,78]. One
population- and one clinic-based study suggest that
MOH can be successfully managed in a primary care
setting after an initial collaboration with headache spe-
cialists [45,79].
The common headache disorders require no high-tech
investigations and may therefore be diagnosed and
managed by all skilled physicians. Most headaches are
therefore probably best managed in primary care. Focus
on MOH in primary care is therefore important both in
order to prevent MOH from developing and for early
diagnosis and treatment.
We have designed a BI for treatment of MOH in pri-
mary care and planned a double-blinded cluster rando-
mized parallel controlled trial (RCT) to evaluate effects
of the intervention.
Objectives
The primary objective is to evaluate the effects of a brief
intervention (BI) versus business as usual (BAU) in the
management of MOH in primary care.
Methods/Design
Our hypothesis is that BI is more effective than BAU.
The hypothesis will be tested using a double-blinded
cluster randomised parallel controlled clinical trial in
primary care comparing BI and BAU three months after
study inclusion and with additional open one year
follow-up (Figure 1).
Setting
The Norwegian GP list-patient system was established in
2001. The GPs are reimbursed through a fixed annual
fee and fees for the specific services from the National
Health Insurance and the patients. GPs act as gate kee-
pers for referrals to secondary care specialists and hospi-
tals except in emergencies. GP specialists must renew
their specialty every fifth year. As a part of this process,
clinical training courses and participation in peer con-
tinuous medical education (CME) group meetings are
compulsory. GPs in the same practice often attend the
same peer CME group, each group typically comprised
of four to ten GPs from different practices. The study
will be undertaken among GPs attending CME groups in
south-eastern Norway.
Recruitment, randomization and blinding
GPs
Recruitment of the GPs will be done by inviting a num-
ber of GPs’ peer CME groups to a Brief Intervention
Course (BIC). Randomisation of GPs (and thereby their
patients) to either BI or BAU will be performed by an
external statistician. Each GP and his/her patients de-
fines one cluster. For practical reasons and to avoid
carry-over effects, the CME groups will be the random-
isation unit.
GPs in half of the CME groups will receive the BIC
and apply BI on their own patients, while the others will
run their clinical practice as usual (BAU).
Patients
A short validated screening questionnaire for headache
[80,81] including questions about headache frequency,
intensity (as recorded on a visual analogue scale (VAS)
[82]), presence of migraine and medication use will be
mailed to all 18–50 year old patients on participating GPs’
patient lists. Names and addresses will be extracted from
GP lists using a specially designed software (Mediata Ltd,
Tønsberg, Norway). One written reminder will be sent to
non-responding patients.
All patients with 15 or more days with self-reported
headache per month and headache medication utili-
zation on 10 days or more per month will be invited to
participate.
Patients unable to participate in an interview in
Norwegian will be excluded.
Baseline patient information (screening questionnaire
and headache diary) will be collected by the Akershus
University hospital research administration unit before
any study-related contact between patient and their GP.
To avoid unblinding and carry-over of information
from the BI to BAU, both GPs and patients will initially
only receive basic information that this study aims to
evaluate headache and headache care in primary care.
After the intervention part, all follow-ups will be con-
ducted by the first author (ESK), who will be blinded in
relation to which treatment the participant has received.
All participating patients will receive a semi-structured
interview and clinical and neurological examination.
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Population controls
1. Control group; random sample without chronic head-
ache (headache if present must be <15 days per month)
based on the screening questionnaire. This group will be
used to control for burden of headache in terms of
quality of life and costs. It will also be used for drop-out
analyses.
2. Chronic headache control group; random sample with
headache ≥15 days per month but without medication
overuse based on the screening questionnaire. This
group will be used as a control for the natural course of
chronic headache as well as for drop-out analyses.
Intervention
Brief intervention course (BIC)
The participating GPs will receive a one day course held
by headache specialists (CL and ESK). It includes general
lectures about migraine, tension-type headache and
chronic headaches, especially MOH. A presentation of
the Brief Information scheme will be given with practical
instructions examplified by role play. Participating GPs
will earn CME credits by the Norwegian Medical Associ-
ation as part of the GP training curriculum. In general,
most of these physicians have previously not received
specific training in the handling of MOH. However, in-
formation on possible previous participation in such
training will be collected.
Brief intervention (BI)
GPs allocated to the BIC will receive information about
screening-positive patients on their lists. These patients
will be invited to a consultation for headache by the GP.
BI will then be performed as follows (for more details
see flow-chart, Figure 2):
1. Use of the SDS questionnaire (Table 1) to identify
patients at risk for MOH, i.e. SDS cut-off values ≥5
(females) and ≥4 (males) [30,35,36]. Inform the patient
that he or she is identified as being at risk for MOH.
Patients with SDS score under cut-off will also receive a
structured intervention and information about the rela-
tionship between drug intake and headache and the im-
portance of staying within “safe levels” of medication use.
2. Give short structured information about MOH and
the association between medication overuse and chronic
headache.
3. Give specific individualised information and advice
regarding reduction of acute headache medication.
Headache classification
The headaches will be classified according to explicit
diagnostic criteria of the ICHD-II and it‘s relevant revi-
sions [83-86]. In this study we have defined chronic
headache as 15 or more headache days per month for at
least 3 months and/or 180 or more headache days per
0 3 6 9 12 months
GPs:
BIC early
BIC late
BI
BAU
Investigator 
group:
Teaching BIC Interview Tel.interv-(Tel.interv.)
Patients:
2w.Diary: (       )
Screen Interv. Tel.interv.(Tel.interv.)
BI
BAU
MOH
GPs Investigator groupAdmin.
BI
blinded open follow-up
BI
Main out-
come
Figure 1 Flow-chart of study. Figure illustrates main time line with the different phases with those mainly responsible for each phase
(lower part). Upper part shows time-points for Patients data collection (2 week headache diaries (2w.diary) and interviews) as well as timing of
various moments for the Investigator group and GPs with Brief Intervention training courses (BIC) for GPs and intervention (Brief intervention - BI
and Business as usual – BAU respectively). Main outcome time-point at 3 months depicted with double arrow and bold writing. BI, Brief
intervention; BIC, Brief Intervention course early or late; BAU, Business as usual; GP, General practitioner; Rand, randomisation.
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year as the ICHD-II does not provide an explicit defin-
ition for all headache diagnoses. The ICHD-II diagnosis
will be made by the first author and by consensus in the
project team based on the 3 month follow-up interview.
Headache diary
A modified version of a validated headache diary [87,88]
will be used in order to prospectively record data on
headache frequency, headache intensity (VAS) and medi-
cation. We have also added self-reported number of sick-
leave days. The completion of the diary for a two week
period will be required at baseline, at three, six and
twelve months for both BI and BAU patients. Written
instructions for the completion of the diary will be
mailed to the patients.
Blinded three months follow-up
Three months after the intervention (or after recruit-
ment to the BAU arm), the patients will be invited to a
clinical interview with an examination focusing on diag-
nosis of headache, relevant comorbidity, use and quanti-
fication of prescription drugs as well as OTC drugs. The
interviewer will be blinded as to which study arm the
patients are allocated to and the patients will be blinded
as to intervention, outcomes and aim of study.
Additional questionnaires will be completed by the
patients (Table 2) in order to cover headache related
Below SDS cut-off
Modified BI
GP invites patient for headache consultation, SDS performed by GP
”With your present medication use you 
are probably not at risk for MOH.”
However, give information about MOH, 
which medications may be involved and 
establish risk levels (number of days of 
overuse defining MOH)
Followed up for chronic headache by 
GP “business as usual”
Above SDS cut-off   
Full individualised BI
Information about MOH, which medications may 
be involved and established risk levels (number 
of days of overuse defining MOH)
Information about gain (headache improvement, 
less risk of medication side effects, better 
responsiveness to prophylactics, cost, quality of 
life, more precise headache diagnosis without 
overuse) 
associated with detoxification and pattern of 
improvement to be expected (initial worsening 
prior to improvement)
Individual aim negotiated: 
generally recommended to terminate overuse 
completely, register headache pattern in diary 
and re-evaluation of remaining headache and 
possible prophylactics after 3 months.
Informal personalised “AIMS and PLAN” 
document including GPs suggestion of how 
patient will be supported (eg. fixed telephone 
contacts, agreement that patient can contact at 
need etc)
Info about screening positive patients (>15 headache days/month, >10 medication days/month) sent to GP
Figure 2 Flow-chart of GPs Brief Intervention for MOH strategy.
Table 1 The five questions of the Severity Dependence Scale (SDS) adapted for headache medication
1. Do you think your use of headache medication was out of control? (never/almost never=0, sometimes=1, often=2, always/nearly always=3)
2. Did the prospect of missing a dose make you anxious or worried? (scoring as for question 1)
3. Did you worry about your use of your headache medication? (scoring as for question 1)
4. Did you wish you could stop? (scoring as for question 1)
5. How difficult would you find it to stop or go without your headache medication? (not difficult=0, quite difficult=1, very difficult=2, impossible=3)
“Your headache medication” will in the interview be replaced with the name of the individually relevant headache medication. Each item will be scored on a 4-point
scale (0–3), and the total maximum score is 15.
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health and quality of life, use of health services, socioe-
conomic and demographic data.
Twelve months follow-up
A re-interview of participants from both study arms
done by telephone by the same interviewer will be per-
formed after one year focusing on headache diagnosis,
use of medication, and present burden of headache
(number of headache days and intensity of headache).
Headache associated quality of life will be assessed with
MIDAS and HIT-6. SDS will be measured.
Outcome measures
Outcome measures are listed in Table 3. Primary out-
comes are headache days and medication days per month
comparing the two arms and change compared to base-
line. With a simple, non-medication intervention as the
present, any significant improvement in these para-
meters is judged to be of relevance. Proportions fulfilling
commonly used clinical definitions of chronic headache
(≥15 days/month) and medication overuse [75-78] at fol-
low up are also clinically relevant and included as
secondary outcomes. In addition, since clinically relevant
outcomes in medication studies have been suggested to be
25 to 50% improvement in headache days and headache
index, these are also included as secondary outcomes.
Data handling and statistical analyses
Power calculations
According to the Norwegian Medical Association, the
average number of listed patients pr GP is approximately
1200. Using 1000 patient pr GP (simplicity) gives us
(based on previous studies [4,5]) an estimate of approxi-
mately 30–40 patients with chronic headaches and 10
patients with MOH per GP.
Using previous results from studies from Akershus
University Hospital [76] regarding number of days of
medication intake per month and proportion of patients
with headache more than 15 days per month before and
after unstructured information about MOH, we have
made an approximation of the required sample size.
Using 80% power for the detection of a similar sized
difference as found in the previous study for number
of days of medication intake [76], we would need 18
Table 2 Validated questionnaires used for additional outcomes with comments regarding relevance for present study
and references to the literature list
Validated questionnaire Description of questionnaire Importance in present study Ref.
Short Form-36 (SF-36) Most used general
QoL questionnaire
Enables quality of life
comparison with non-headache
patients from the general
population ., normal material
for Norwegian population exists
[89-91]
Migraine Disability
Assessment (MIDAS)
Headache Impact
Test – 6 (HIT-6)
Most used headache
specific QoL instruments,
recommended for RCTs
of headache treatment
Enables comparison
between various headache
categories
[92,93]
Severity of Dependence
Scale (SDS)
Validated for detection
of MOH in previous studies
Simple identification of MOH
patients, comparison against
scores for other addictive drugs
[58,94]
Mini International
Neuropsychiatric
Interview (MINI)
Validated structured
interview for DSM-IV based
diagnosis of substance
dependency
Gold standard for dependency
for validation of SDS
[58,94]
Eysenck Personality
Questionnaire (EPQ)
Widely used personality
scale both in relation to
drug dependency and in
more general
Assessment of personality
as a factor which may affect
outcomes after a behavioural
intervention, Norwegian
population standards exist
[95-97]
Hopkins Symptom
Checklist-25 (HSCL-25)
Well validated scale for
symptoms of psychological
distress
Supplement to Eysenck for
assessing degree of distress
which may affect outcomes
of behavioural intervention,
Norwegian population
standards exist
[98-100]
Hospitality and Anxiety
Depression Scale (HADs)
Most used scale in clinical
materials for scoring depressive
and anxiety symptoms
Assessment of depression
and anxiety as comorbidities
of chronic headache which
may affect outcomes of
intervention, Norwegian
population standards exist
[101,102]
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patients in each arm unadjusted and five clusters (ie. GPs)
with eight patients each, to achieve significant results
at the 5% level. For analysis of the proportion of pa-
tients with more than 15 days of headache, power cal-
culations yield 30 patients or eight clusters (GPs) with
eight patients each. Since the intra-cluster coefficient
of correlation is not known (here estimated at 0.5 as a
“worst case”) and since we don’t know the degree of
carry-over of information from one group of GPs to
another, we assume a sample size of 20 physicians
(160 patients) to be reasonably safe. This would also
give significant results at the 5% level even if only five
patients per GP were included.
Statistics
All analyses will be focused at the patient level (inference
unit will be patient). We will perform a series of fre-
quency analyses tabulating outcome variables against
various explanatory variables and/or confounders. Suit-
able descriptive statistics will be used. Since individual
observations within the same cluster (ie. patients of one
GP) may be correlated, the intra-cluster (intra-class) cor-
relation coefficient (ICC) measuring such a “clustering
effect” and estimating the relative variability within and
between clusters will be calculated for both intervention-
and control groups. Analysis of differences between BI-
and BAU groups based on mixed linear models (MLM)
will be performed to account for the hierarchical na-
ture of data, where the main point is to allow variation
to be modelled at each level of the data, for example,
the GP and the patient level. 95% confidence intervals
will be used.
Analysis based on prespecified hypotheses regarding
the two primary and the secondary outcomes will be
performed as hypothesis testing on the entire dataset
and Bonferroni corrections will be used for multiple
Table 3 Outcome measures and time points for application of the various outcomes (statistical calculations are further
described in the Statistics section)
3 months 12 months
Primary outcomes
Difference between BI and BAU in:
a) number of headache days per month X
b) number of headache medication days per month X
Change relative to baseline in
a) number of headache days per month X
b) number of headache medication days per month X
Secondary outcomes
Difference between BI and BAU in proportion of cases without
chronic headache and without medication overuse
X
Change relative to baseline in proportion of patients with more than
a) 25% reduction of headache days X X
b) 50% reduction of headache days X X
Change relative to baseline in headache index (Area under
curve for headache intensity versus time)
X X
Change relative to baseline in
a) headache days from headache diary X X
b) medication days from diary X X
Change relative to baseline in average headache intensity recorded
by VAS (from headache diary)
X X
Change relative to 3 month follow-up in self-reported health related costs X
Change relative to 3 month follow-up in quality of life recorded as
SF-36 and MIDAS/HIT-6
X
Change relative to baseline in:
a) number of headache days per month X
b) number of headache medication days per month X
Relapse rate compared with status at 3 month X
Abbreviations: BI brief intervention, BAU business as usual, VAS visual analogue scale, SF-36 short form-36, MIDAS migraine disability assessment score, HIT-6
headache impact test-6.
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comparisons. For evaluation of possible outcome predic-
tors where no prior data from this population exist, split
file analysis [103] will be used. The splitting of the data
set will be performed prior to any analyses of primary
and/or secondary outcomes.
The intention-to-treat principle will be followed by in-
cluding all patients with at least one follow-up response.
Missing values will be handled using multiple imput-
ation techniques.
SPSS 16.0 and SAS will be used for statistical analyses.
Registration of electronic data from the semi-structured
interviews will be done by using Snap Survey (Snap
Survey, London, UK).
The participating patients will receive a weekly re-
minder regarding the headache diary via mobile phone
(SMS) during each two weeks diary period at three, six
and twelve months, respectively.
Ethics and data security
The study has been approved by the Regional Commit-
tee for Medical Research Ethics, the Norwegian Social
Science Data Services (NSD) and the Norwegian Direct-
orate for Health.
All data will be anonymised. All participating patients
and GPs must give informed, written consent. The ap-
proval of the Regional Committee for Medical Research
Ethics was given based on a possibility of a cross-over
from the control group to the intervention group if the
main outcomes at three months show a significant bene-
ficial effect of BI. This is to avoid a six months delay in
offering effective treatment. In that case, the GPs in the
BAU arm will receive the BIC and be able to perform BI
on their own MOH patients.
Pilot study
The intervention has been be tested for practicability
and acceptability in a pilot study with six GPs. The pilot
study did not involve a control group. Recruitment
methodology and logistics were tested. Patients from the
pilot study will not be included in the main study.
Dissemination/feedback of results
After the study, feedback will be given to the involved
GPs regarding the efficacy of BI and main outcomes. In
addition, we aim to publish the results in international
peer-reviewed scientific journals and disseminate our
experiences in national medical fora.
Discussion
There is no consensus for MOH withdrawal programmes
and there is therefore a need for evidence-based and
cost-effective strategies for MOH [36,37].
To our knowledge, this is the first double-blinded cluster-
randomized controlled clinical trial for MOH in primary
care.
The GPs that will be included in the present study are
assumed to be representative for Norwegian GPs in gen-
eral in terms of localisation (urban vs. suburban), gender
and age distribution. Through the Norwegian GP list-
patient system, all citizens are listed with a GP. There-
fore, with a representative selection of GPs, the patient
population is assumed to be reasonably population-
based which will increase the external validity of our
findings.
The age range of patients (18–50 years of age) has
been chosen in order to target the highest number of
patients with chronic headache, as the prevalence is
lower in younger people and older people have a higher
frequency of co-morbidities. We have chosen an upper
age limit of 50 years since data from the Norwegian pre-
scription database (NorPD) also indicate that there is an
increase in the number and dosage of various relevant
drugs (notably anti-hypertensives and cardiovascular
drugs) at approximately 50 years of age [104] and we
want to monitor headache medication and not the use
of drugs prescribed for other illnesses.
Selection bias may occur by just including patients
who are willing to cooperate in the intervention; how-
ever the same selection will take place in the control
group. The selection of participating GPs are based on
voluntary participation and the BIC will give them CME
credits. Our GPs might therefore have a higher motiv-
ation for the BI than GPs in general, but this selection
will also take place in the control group. Gains for par-
ticipating GPs are: i) improvement in headache diagnos-
tics and management ii) receiving a tool for identifying
and detoxifying MOH patients.
The study group will cover the normal fee for the BI
consultation for the patients, apart from this there are
no economic incentives for participation either for the
patients or the GPs.
Although questionnaires cannot replace an encounter
with a skilled physician, single questions about migraine
and tension-type headache and frequency of tension-
type headache have been shown to be valid [80,81].
However, especially among those with chronic or co-
occurring headache types, diagnosing headaches is not
always easy. The gold standard for making a specific
headache diagnosis is an interview combined with a
physical and neurological examination by a physician
experienced in headache diagnostics. All patients will be
diagnosed based on interviews by a GP trained and
experienced in headache diagnostics also in order to
avoid inter-observer variation (ESK).
Some of our data will be based on retrospective self-
reports and therefore open to recall bias, although here
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is no reason to suspect systematic bias. In order to
counteract this, we will also use headache data from pro-
spective headache diaries [87]. Recent studies using a
similar headache diary with written instructions before
first consultation found high usefulness, acceptability
and comprehensibility of the diary as well as good com-
pliance and completeness of data [105,106]. We will use
the headache diary for periods of two weeks. This period
may seem too short for infrequent forms of headache,
but in our sample of chronic sufferers this should not be
a problem. In addition, a longer headache registration
period may reduce compliance and cause greater inter-
ference with the cohort.
A common finding in many brief intervention stud-
ies and RCTs on alcohol use, are small reductions in
alcohol consumption at follow-up also in the control
group [73,107]. Possible reasons for this may be motiv-
ational effects of screening, sensitization to screening/
measurements/follow-up, non-intended advice also in
BAU group, and “regression towards the mean”. In this
study we have tried to minimize most assessment ef-
fects by doing a double-blinded parallel RCT, and the
screening questionnaire about medication use for head-
ache is embedded with other questions about headache
in the very short screening questionnaire. The control
group will not receive the SDS screening before the
three months follow-up and will therefore not be af-
fected by this.
The SDS has not been validated against other mea-
surements of dependency in MOH sufferers and, indeed,
there is still much discussion as to whether MOH repre-
sents dependency [50-55,57]. Being fully aware of this,
we will use the SDS score, not as an attempt to define
dependency, but rather to distinguish between chronic
headache subjects with and without medication overuse
[30,35].
A Danish study has shown that feasibility, acceptability
and implementation of screening and brief intervention
programs for alcohol overuse in primary care may cause
more problems than they solve for some GPs because it
might be problematic to incorporate a brief intervention
and follow-up in a busy daily practice where many other
different problems are targeted [108]. It is clear that if
physicians, and especially GPs, are to deliver interven-
tions in a busy daily and routine practice, it is of great
importance that the interventions are feasible and con-
sidered clinically relevant. We have used knowledge and
experience from a study on the epidemiology of head-
ache in Norway [5,6], a prescription peer academic de-
tailing study [109,110], and a pilot study to investigate
some of these aspects, and used this to design the final
structure and contents of both the BIC and the study to
be both acceptable for patients and feasible for GPs in
daily practice.
To reduce the workload for participating GPs as well
as for blinding purposes, the first universal/opportunistic
screening for chronic headache and probable medication
overuse will be performed by the external project admin-
istration prior to the BI. Through this screening we also
expect to reach possible chronic headache patients who
might not be known as such by their GP. Apart from
this initial screening, the study is a pragmatic trial tai-
lored to fit into a busy situation of an everyday GP.
We suggest that strengths of this study include the de-
sign and approach with randomly assigned intervention
and control groups in accordance with the CONSORT
statement for RCTs [111].
The present project holds potentials for making a
change in the focus on MOH treatment in particular, as
well as the medication use for chronic headache in gen-
eral. The dissemination of the results and of the BI
methods to inform the Norwegian health care system
will be possible because of the primary care strategy.
There is a potential of reducing the suffering of MOH in
a large, but so far largely neglected group of patients. Ef-
fective treatment at the GP-level, is also an advantage if
it does not lead to more referrals to specialists. The
principle of treatment at the lowest effective level of
care, in this case in primary care, is a stated aim in the
Norwegian health care system where also the geograph-
ical situation often reduces the accessibility to secondary
health care services. In addition, a reduction in medica-
tion costs, improved headache status, and reduced sec-
ondary headache related costs, may lead to economical
savings for society as well as benefits for the individual
patients. Such effects may potentially be augmented by a
greater awareness of GPs, pharmacists and society in
general regarding dangers associated with indiscriminate
use of pain killers for frequent headache.
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